Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers (U54) | Apply Online

Frequently Asked Questions (FAQs): Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers (MDCRCs)

1) What is the Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers (MDCRCs) program?

The MDCRCs program is a National Institutes of Health (NIH) funding opportunity to support large, team-based research centers focused on advancing muscular dystrophy discoveries toward real-world treatments. It is intended to expand and strengthen a coordinated network of Wellstone Centers working on translational objectives.

2) What is the main goal of this funding opportunity?

The main goal is to accelerate the translation of emerging scientific findings and technological advances into new therapeutic options for one or more forms of muscular dystrophy. The program emphasizes work that is most effective when organized as an integrated center rather than as separate, isolated projects.

3) What kinds of applications are being solicited (Type 1 vs. Type 2)?

The announcement solicits both new center applications (Type 1) and competitive renewals of existing centers (Type 2).

4) What funding mechanism is used for this program?

Funding is provided through a U54 Specialized Centers Cooperative Agreement.

5) How is a U54 cooperative agreement different from a standard research grant?

A U54 cooperative agreement is distinct from a standard research project grant because it typically involves a more active partnership with NIH program staff. Cooperative agreements generally imply substantial NIH involvement in coordination, oversight, and alignment with broader program goals, consistent with operating as part of a national network of centers.

6) What is the program emphasis: basic science, translational research, or clinical research?

The program is specifically oriented around the therapeutic development pipeline. Centers may include a blend of basic, translational, and clinical research, but the work needs to be tied directly to practical steps required for therapy development.

7) What does it mean that the FOA is "oriented around the therapeutic development pipeline"?

It means the research should be designed to move from discovery toward testable interventions by addressing the concrete steps that enable therapy development, including preclinical work, biomarker and diagnostic development, regulated advancement steps (such as IND-enabling activities), and early clinical evaluation.

8) What research activities are explicitly described as examples of what this program can support?

Examples include identifying and validating therapeutic targets; developing diagnostics and biomarkers to characterize disease or stratify patient populations; creating and improving in vitro assays; developing and characterizing animal models; screening candidate therapeutics for efficacy; conducting preclinical optimization work; and completing FDA-related activities needed to advance a candidate toward an Investigational New Drug (IND) application.

9) Does the opportunity support FDA-related and IND-enabling activities?

Yes. The FOA explicitly includes completing FDA-related activities needed to advance a candidate toward an Investigational New Drug (IND) application as an example of supported work.

10) What clinical activities can be included in a center application?

On the clinical side, the FOA supports building or leveraging clinical infrastructure to enable trials, conducting patient-oriented natural history studies to clarify disease progression, and performing early-stage clinical trials.

11) Are natural history studies allowed under this opportunity?

Yes. The FOA includes patient-oriented natural history studies that clarify disease progression as a supported activity.

12) Are early-stage clinical trials within scope?

Yes. The FOA includes performing early-stage clinical trials as an example of supported clinical work.

13) What is the role of collaboration in this program?

Collaboration and multidisciplinary integration are major themes. Applicants are expected to propose coordinated research efforts that address one or more bottlenecks in muscular dystrophy therapy development, ideally by bringing together complementary expertise across disciplines.

14) What kinds of expertise does the FOA suggest could be part of a Wellstone Center team?

The FOA highlights complementary expertise such as molecular and cell biology, bioengineering, animal modeling, biomarker science, clinical neurology, rehabilitation, biostatistics, clinical trial operations, and regulatory strategy.

15) What types of problems is this center-based structure intended to address?

The FOA signals that the scientific problems should be complex enough to require substantial cooperative effort and that a center-based structure should be the most effective way to produce progress. In practical terms, centers should target bottlenecks and key gaps that keep promising ideas from becoming testable, regulated, and clinically meaningful interventions.

16) Does the program focus on a single type of muscular dystrophy?

The FOA is described as supporting therapeutic development for one or more forms of muscular dystrophy, rather than limiting the opportunity to only one type.

17) How many awards are expected under this announcement?

The expected number of awards is about three.

18) What is the estimated total funding and the award ceiling?

The estimated total funding listed is $3,000,000, and the award ceiling is $1,000,000.

19) Is cost sharing or matching required?

No. The opportunity states that there is no cost sharing or matching requirement.

20) What is the Funding Opportunity Number for this announcement?

The Funding Opportunity Number is RFA-HD-09-027.

21) When was the opportunity posted and what was the application deadline?

The opportunity was posted on May 13, 2009, and the application deadline was November 10, 2009.

22) What is the activity category associated with this opportunity?

The activity category is listed under Health, Income Security, and Social Services.

23) What CFDA areas are associated with the program?

The program is tied to multiple CFDA numbers reflecting NIH disease and institute research areas, including cardiovascular, arthritis/musculoskeletal/skin, neurosciences/neurological disorders, and child health and human development extramural research programs.

24) What types of organizations are eligible to apply?

Eligible applicants include public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations (including those with and without 501(c)(3) status, other than institutions of higher education), and for-profit organizations other than small businesses.

25) Does the eligibility language mention institutions serving specific populations?

Yes. The eligibility section highlights inclusion of institutions serving specific populations, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, and Alaska Native and Native Hawaiian-serving institutions.

26) Why does the FOA emphasize being part of a coordinated network of centers?

The FOA frames the program as a coordinated NIH-supported network aimed at accelerating tangible treatment progress. The cooperative agreement structure and the emphasis on center-based, integrated projects support parallel and coordinated translational efforts across multiple Wellstone Centers.

27) What is the overall "fit" of a strong application based on the description provided?

Based on the information provided, a strong application would propose high-impact, highly collaborative center research that connects discovery science to regulated therapeutic development and early clinical testing, and that benefits from being run as an integrated center tackling defined bottlenecks in the therapy development pipeline.